Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding.

ABSTRACT:

Background

Randomized trials suggest that direct oral anticoagulants (DOACs) are at least as effective as warfarin for primary treatment of VTE and that bleeding risk may be lower for some DOACs relative to warfarin. However, there is very little information regarding potential bleeding risks for DOACs versus warfarin in secondary prevention of VTE.

Objective

The aim of this study was to compare rates of bleeding events resulting in inpatient admissions between individuals taking apixaban, rivaroxaban, and warfarin for secondary prevention of VTE during the period 2013-2017.

Methods

We used the IBM MarketScan Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database (IBM Watson Health, Ann Arbor, MI) to establish a retro

SUBMITTER: MacLehose RF 

PROVIDER: S-EPMC8105158 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature